Recent studies have shown impressive cardiovascular health benefits in individuals treated with SGLT2 inhibitors (SGLT2i) regardless of diabetic status. The underlying mechanisms driving these benefits are not well understood. Recently in Circulation, Griffin et al. (2020) reported the first human study investigating the diuretic effect of empagliflozin.

中文翻译：

---

SGLT2 抑制剂：不是传统的心力衰竭利尿剂。

最近的研究表明，无论糖尿病状态如何，接受 SGLT2 抑制剂 (SGLT2i) 治疗的个体的心血管健康益处令人印象深刻。驱动这些好处的潜在机制尚不清楚。最近在循环中，格里芬等人。(2020) 报道了第一项调查恩格列净利尿作用的人体研究。